In 2013, Bissler et al[19] undertook a placebo-controlled trial with another mTOR inhibitor, everolimus, and reported that 50% AML shrinkage was achieved in 42% of patients who received everolimus and 0% in the placebo arm. Here, MTOR is linked to acute myeloid leukemia.